Compare Inovio Pharmaceuticals Inc (INO) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Rush Street Interactive Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M), while Rush Street Interactive Inc trades at $19.38 (market cap $2.35B). The key difference: Rush Street Interactive Inc is far larger — about 20.9× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is more actively traded (3,201,278 versus 2,219,374). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Rush Street Interactive Inc for 13 Days on average.
| INO | RSI | |
|---|---|---|
Market Cap | $112.19M | $2.35B |
Volume | 3,201,278 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $34.52 |
52-Week Low | $0.66 | $15.89 |
Typical Hold Time | 43 Days | 13 Days |
Enterprise Value | $83.51M | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
RSI trades at $19.89, down 1.73% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.15, beating estimates, and revenue growth to $1.4 billion projected for 2026. Analyst consensus is strongly bullish with a $34.88 price target, though net income margins remain thin at 2.33%.
The stock presents a mixed outlook: strong analyst support and revenue growth contrast with high valuation multiples and bearish technical trends. Key risks include competitive pressures in online gaming and reliance on sports betting cycles. Upside depends on margin improvement and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
